{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:29:24Z","timestamp":1789104564056,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["05817, 02695, 06086"],"award-info":[{"award-number":["05817, 02695, 06086"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00259-019-04297-5","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T11:02:59Z","timestamp":1553598179000},"page":"1276-1286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis"],"prefix":"10.1007","volume":"46","author":[{"given":"Antoine","family":"Leuzy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Savitcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Chiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lilja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenad","family":"Bogdanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Jelic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta","family":"Nordberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"4297_CR1","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/ene.13728","volume":"25","author":"F Nobili","year":"2018","unstructured":"Nobili F, Arbizu J, Bouwman F, Drzezga A, Agosta F, Nestor P, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain (18)F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018;25:1201\u201317. \n                    https:\/\/doi.org\/10.1111\/ene.13728\n                    \n                  .","journal-title":"Eur J Neurol"},{"key":"4297_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010632.pub2","volume":"1","author":"N Smailagic","year":"2015","unstructured":"Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C. (18)F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015;1:CD010632. \n                    https:\/\/doi.org\/10.1002\/14651858.CD010632.pub2\n                    \n                  .","journal-title":"Cochrane Database Syst Rev"},{"key":"4297_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614\u201329. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(14)70090-0\n                    \n                  .","journal-title":"Lancet Neurol"},{"key":"4297_CR4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306\u201319. \n                    https:\/\/doi.org\/10.1002\/ana.20009\n                    \n                  .","journal-title":"Ann Neurol"},{"key":"4297_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jamaneurol.2014.4143","volume":"72","author":"GD Rabinovici","year":"2015","unstructured":"Rabinovici GD. The translational journey of brain beta-amyloid imaging: from positron emission tomography to autopsy to clinic. JAMA Neurol. 2015;72:265\u20136. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2014.4143\n                    \n                  .","journal-title":"JAMA Neurol"},{"key":"4297_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","volume":"71","author":"TG Beach","year":"2012","unstructured":"Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71:266\u201373. \n                    https:\/\/doi.org\/10.1097\/NEN.0b013e31824b211b\n                    \n                  .","journal-title":"J Neuropathol Exp Neurol"},{"key":"4297_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3233\/JAD-2012-121216","volume":"33","author":"EP Klein","year":"2013","unstructured":"Klein EP, Kaye J. Dementia specialists and early adoption of amyloid imaging. J Alzheimers Dis. 2013;33:445\u201350. \n                    https:\/\/doi.org\/10.3233\/JAD-2012-121216\n                    \n                  .","journal-title":"J Alzheimers Dis"},{"key":"4297_CR8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3233\/JAD-171093","volume":"63","author":"ER Fantoni","year":"2018","unstructured":"Fantoni ER, Chalkidou A, O\u2019Brien JT, Farrar G, Hammers A. A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer's disease. J Alzheimers Dis. 2018;63:783\u201396. \n                    https:\/\/doi.org\/10.3233\/JAD-171093\n                    \n                  .","journal-title":"J Alzheimers Dis"},{"key":"4297_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-180239","volume":"64","author":"YF Shea","year":"2018","unstructured":"Shea YF, Barker W, Greig-Gusto MT, Loewenstein DA, Duara R, DeKosky ST. Impact of amyloid PET imaging in the memory clinic: a systematic review and meta-analysis. J Alzheimers Dis. 2018;64:323\u201335. \n                    https:\/\/doi.org\/10.3233\/JAD-180239\n                    \n                  .","journal-title":"J Alzheimers Dis"},{"key":"4297_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jalz.2017.09.009","volume":"14","author":"M Ceccaldi","year":"2018","unstructured":"Ceccaldi M, Jonveaux T, Verger A, Krolak-Salmon P, Houzard C, Godefroy O, et al. Added value of (18)F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: a naturalistic study. Alzheimers Dement. 2018;14:293\u2013305. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2017.09.009\n                    \n                  .","journal-title":"Alzheimers Dement"},{"key":"4297_CR11","doi-asserted-by":"publisher","unstructured":"Boccardi M, Altomare D, Ferrari C, Festari C, Guerra UP, Paghera B, et al. Assessment of the incremental diagnostic value of florbetapir F18 imaging in patients with cognitive impairment: the Incremental Diagnostic Value of Amyloid PET with [18F]-Florbetapir (INDIA-FBP) Study. JAMA Neurol. 2016;73:1417\u201324. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2016.3751\n                    \n                  .","DOI":"10.1001\/jamaneurol.2016.3751"},{"key":"4297_CR12","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3233\/JAD-151180","volume":"52","author":"MR Bensaidane","year":"2016","unstructured":"Bensaidane MR, Beauregard JM, Poulin S, Buteau FA, Guimond J, Bergeron D, et al. Clinical utility of amyloid PET imaging in the differential diagnosis of atypical dementias and its impact on caregivers. J Alzheimers Dis. 2016;52:1251\u201362. \n                    https:\/\/doi.org\/10.3233\/JAD-151180\n                    \n                  .","journal-title":"J Alzheimers Dis"},{"key":"4297_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-016-0228-4","volume":"9","author":"MD Zwan","year":"2017","unstructured":"Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FR, et al. Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017;9:2. \n                    https:\/\/doi.org\/10.1186\/s13195-016-0228-4\n                    \n                  .","journal-title":"Alzheimers Res Ther"},{"key":"4297_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1750-1326-9-10","volume":"9","author":"EM Mitsis","year":"2014","unstructured":"Mitsis EM, Bender HA, Kostakoglu L, Machac J, Martin J, Woehr JL, et al. A consecutive case series experience with [18F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition. Mol Neurodegener. 2014;9:10. \n                    https:\/\/doi.org\/10.1186\/1750-1326-9-10\n                    \n                  .","journal-title":"Mol Neurodegener"},{"key":"4297_CR15","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jalz.2012.07.003","volume":"9","author":"R Ossenkoppele","year":"2013","unstructured":"Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, van der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9:414\u201321. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2012.07.003\n                    \n                  .","journal-title":"Alzheimers Dement"},{"key":"4297_CR16","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1001\/jamaneurol.2018.0894","volume":"75","author":"DA Wolk","year":"2018","unstructured":"Wolk DA, Sadowsky C, Safirstein B, Rinne JO, Duara R, Perry R, et al. Use of flutemetamol F18-labeled positron emission tomography and other biomarkers to assess risk of clinical progression in patients with amnestic mild cognitive impairment. JAMA Neurol. 2018;75:1114\u201323. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2018.0894\n                    \n                  .","journal-title":"JAMA Neurol"},{"key":"4297_CR17","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","volume":"75","author":"A Wilde de","year":"2018","unstructured":"de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol. 2018;75:1062\u201370. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2018.1346\n                    \n                  .","journal-title":"JAMA Neurol"},{"key":"4297_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1212\/WNL.0000000000002081","volume":"86","author":"MD Zwan","year":"2016","unstructured":"Zwan MD, Rinne JO, Hasselbalch SG, Nordberg A, Lleo A, Herukka SK, et al. Use of amyloid-PET to determine cutpoints for CSF markers: a multicenter study. Neurology. 2016;86:50\u20138. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000002081\n                    \n                  .","journal-title":"Neurology"},{"key":"4297_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303\u20138.","journal-title":"Arch Neurol"},{"key":"4297_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","volume":"256","author":"B Winblad","year":"2004","unstructured":"Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment \u2013 beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240\u20136. \n                    https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01380.x\n                    \n                  .","journal-title":"J Intern Med"},{"key":"4297_CR21","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology"},{"key":"4297_CR22","volume-title":"The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines","author":"World Health Organization","year":"1992","unstructured":"World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992."},{"key":"4297_CR23","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","volume":"47","author":"IG McKeith","year":"1996","unstructured":"McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology. 1996;47:1113\u201324.","journal-title":"Neurology"},{"key":"4297_CR24","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","volume":"51","author":"D Neary","year":"1998","unstructured":"Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546\u201354.","journal-title":"Neurology"},{"key":"4297_CR25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.43.2.250","volume":"43","author":"GC Roman","year":"1993","unstructured":"Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250\u201360.","journal-title":"Neurology"},{"key":"4297_CR26","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014;10:844\u201352. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2014.01.001\n                    \n                  .","journal-title":"Alzheimers Dement"},{"key":"4297_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1159\/000366270","volume":"4","author":"S Garcia-Ptacek","year":"2014","unstructured":"Garcia-Ptacek S, Cavallin L, Kareholt I, Kramberger MG, Winblad B, Jelic V, et al. Subjective cognitive impairment subjects in our clinical practice. Dement Geriatr Cogn Dis Extra. 2014;4:419\u201330. \n                    https:\/\/doi.org\/10.1159\/000366270\n                    \n                  .","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"4297_CR28","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","volume":"55","author":"P Scheltens","year":"1992","unstructured":"Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in \"probable\" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55:967\u201372.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4297_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000117270","volume":"36","author":"F Pasquier","year":"1996","unstructured":"Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol. 1996;36:268\u201372.","journal-title":"Eur Neurol"},{"key":"4297_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149:351\u20136. \n                    https:\/\/doi.org\/10.2214\/ajr.149.2.351\n                    \n                  .","journal-title":"AJR Am J Roentgenol"},{"key":"4297_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/MNM.0000000000000633","volume":"38","author":"CJ Buckley","year":"2017","unstructured":"Buckley CJ, Sherwin PF, Smith AP, Wolber J, Weick SM, Brooks DJ. Validation of an electronic image reader training programme for interpretation of [18F]flutemetamol beta-amyloid PET brain images. Nucl Med Commun. 2017;38:234\u201341. \n                    https:\/\/doi.org\/10.1097\/MNM.0000000000000633\n                    \n                  .","journal-title":"Nucl Med Commun"},{"key":"4297_CR32","doi-asserted-by":"publisher","unstructured":"Lilja J, Leuzy A, Chiotis K, Savitcheva I, Sorensen J, Nordberg A. Spatial normalization of 18F-flutemetamol PET images utilizing an adaptive principal-component template. J Nucl Med. 2019;60:285\u201391. \n                    https:\/\/doi.org\/10.2967\/jnumed.118.207811\n                    \n                  .","DOI":"10.2967\/jnumed.118.207811"},{"key":"4297_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ana.22068","volume":"68","author":"R Vandenberghe","year":"2010","unstructured":"Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319\u201329. \n                    https:\/\/doi.org\/10.1002\/ana.22068\n                    \n                  .","journal-title":"Ann Neurol"},{"key":"4297_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.neurobiolaging.2017.01.021","volume":"52","author":"M Boccardi","year":"2017","unstructured":"Boccardi M, Gallo V, Yasui Y, Vineis P, Padovani A, Mosimann U, et al. The biomarker-based diagnosis of Alzheimer's disease. 2\u2013lessons from oncology. Neurobiol Aging. 2017;52:141\u201352. \n                    https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.01.021\n                    \n                  .","journal-title":"Neurobiol Aging"},{"key":"4297_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.neurobiolaging.2016.02.033","volume":"52","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Perani D, Bastianello S, Bernardi G, Porteri C, Boccardi M, et al. Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap. Neurobiol Aging. 2017;52:119\u201331. \n                    https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.02.033\n                    \n                  .","journal-title":"Neurobiol Aging"},{"key":"4297_CR36","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.neurobiolaging.2016.07.012","volume":"52","author":"K Chiotis","year":"2017","unstructured":"Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:214\u201327. \n                    https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.07.012\n                    \n                  .","journal-title":"Neurobiol Aging"},{"key":"4297_CR37","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/ana.21559","volume":"65","author":"AM Fagan","year":"2009","unstructured":"Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176\u201383. \n                    https:\/\/doi.org\/10.1002\/ana.21559\n                    \n                  .","journal-title":"Ann Neurol"},{"key":"4297_CR38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","volume":"64","author":"AM Fagan","year":"2007","unstructured":"Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau\/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343\u20139. \n                    https:\/\/doi.org\/10.1001\/archneur.64.3.noc60123\n                    \n                  .","journal-title":"Arch Neurol"},{"key":"4297_CR39","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/brain\/aww015","volume":"139","author":"S Palmqvist","year":"2016","unstructured":"Palmqvist S, Mattsson N, Hansson O. Alzheimer's disease neuroimaging I. Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain. 2016;139:1226\u201336. \n                    https:\/\/doi.org\/10.1093\/brain\/aww015\n                    \n                  .","journal-title":"Brain"},{"key":"4297_CR40","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","volume":"71","author":"S Palmqvist","year":"2014","unstructured":"Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71:1282\u20139. \n                    https:\/\/doi.org\/10.1001\/jamaneurol.2014.1358\n                    \n                  .","journal-title":"JAMA Neurol"},{"key":"4297_CR41","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awu367","volume":"138","author":"N Mattsson","year":"2015","unstructured":"Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease. Brain. 2015;138:772\u201383. \n                    https:\/\/doi.org\/10.1093\/brain\/awu367\n                    \n                  .","journal-title":"Brain"},{"key":"4297_CR42","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535\u201362. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018\n                    \n                  .","journal-title":"Alzheimers Dement"},{"key":"4297_CR43","first-page":"346","volume":"10","author":"I Illan-Gala","year":"2018","unstructured":"Illan-Gala I, Pegueroles J, Montal V, Vilaplana E, Carmona-Iragui M, Alcolea D, et al. Challenges associated with biomarker-based classification systems for Alzheimer\u2019s disease. Alzheimers Dement Diagn Assess Dis Monit. 2018;10:346\u201357.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"4297_CR44","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1007\/s00415-015-7904-3","volume":"262","author":"RW Paterson","year":"2015","unstructured":"Paterson RW, Toombs J, Slattery CF, Nicholas JM, Andreasson U, Magdalinou NK, et al. Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. J Neurol. 2015;262:2722\u201330. \n                    https:\/\/doi.org\/10.1007\/s00415-015-7904-3\n                    \n                  .","journal-title":"J Neurol"},{"key":"4297_CR45","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1093\/brain\/aww160","volume":"139","author":"A Leuzy","year":"2016","unstructured":"Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendonca A, Otto M, et al. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-beta in a multicentre European memory clinic study. Brain. 2016;139:2540\u201353. \n                    https:\/\/doi.org\/10.1093\/brain\/aww160\n                    \n                  .","journal-title":"Brain"},{"key":"4297_CR46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF Abeta42\/Abeta40 and Abeta42\/Abeta38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154\u201365. \n                    https:\/\/doi.org\/10.1002\/acn3.274\n                    \n                  .","journal-title":"Ann Clin Transl Neurol"},{"key":"4297_CR47","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14:1470\u201381. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2018.01.010\n                    \n                  .","journal-title":"Alzheimers Dement"},{"key":"4297_CR48","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2967\/jnumed.116.185017","volume":"58","author":"H Barthel","year":"2017","unstructured":"Barthel H, Sabri O. Clinical use and utility of amyloid imaging. J Nucl Med. 2017;58:1711\u20137. \n                    https:\/\/doi.org\/10.2967\/jnumed.116.185017\n                    \n                  .","journal-title":"J Nucl Med"},{"key":"4297_CR49","doi-asserted-by":"publisher","unstructured":"Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement. 2013;9:E1\u201316. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2013.01.002\n                    \n                  .","DOI":"10.1016\/j.jalz.2013.01.002"},{"key":"4297_CR50","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","volume":"317","author":"MC Donohue","year":"2017","unstructured":"Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS, et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA. 2017;317:2305\u201316. \n                    https:\/\/doi.org\/10.1001\/jama.2017.6669\n                    \n                  .","journal-title":"JAMA"},{"key":"4297_CR51","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.neurobiolaging.2005.07.021","volume":"27","author":"LS Prichep","year":"2006","unstructured":"Prichep LS, John ER, Ferris SH, Rausch L, Fang Z, Cancro R, et al. Prediction of longitudinal cognitive decline in normal elderly with subjective complaints using electrophysiological imaging. Neurobiol Aging. 2006;27:471\u201381. \n                    https:\/\/doi.org\/10.1016\/j.neurobiolaging.2005.07.021\n                    \n                  .","journal-title":"Neurobiol Aging"},{"key":"4297_CR52","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","volume":"172","author":"C Stinton","year":"2015","unstructured":"Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172:731\u201342. \n                    https:\/\/doi.org\/10.1176\/appi.ajp.2015.14121582\n                    \n                  .","journal-title":"Am J Psychiatry"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04297-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04297-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04297-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:08:30Z","timestamp":1585094910000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04297-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4297"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04297-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,26]]},"assertion":[{"value":"6 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"J.L. is an employee of Hermes Medical Solutions, Stockholm, Sweden. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}